Regencell Bioscience
RGC
4.18
-0.18
-4.13%
Regencell Bioscience
US · RGC
#2393 by market cap
Listed 2021
4.18
-0.18
-4.13%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:34
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 7 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 0.34% -0.01pp
- Institutions
- 36 -7
- As of
- 2026/Q3 vs. prior period
Holder types
Individual/Insider88.55%
Mutual Fund0.20%
Other11.12%
Top holders as of 2026-06-30
Yat-Gai Au
88.31% · 437.90M sh
Hoor Han Lo
0.12% · 604.05K sh
Yat-Pui Au
0.12% · 581.51K sh
Geode Capital Management, LLC
0.09% · 423.37K sh
Alyeska Investment Group, L.P.
0.08% · 416.26K sh
FMR
0.06% · 301.86K sh
Legal & General Investment Management
0.03% · 128.00K sh
Jane Street Group, LLC
0.02% · 81.70K sh
XTX Markets Limited
0.01% · 60.06K sh
Amundi Asset Management
0.01% · 47.16K sh
Quadrature Capital Limited
0.01% · 41.75K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
8 filings tracked · 0 buys · 2 sells
| Name | Role | Stake |
|---|---|---|
| Yat-Gai Au | Chairperson & CEO | 88.31% |
| Hoor Han Lo | Independent Director | 0.12% |
| Yat-Pui Au | Chief Business Officer | 0.12% |
| Wing Yan Lo | Independent Director | -- |
| Yee Wah Hui | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-26 | Wing Yan Lo | Independent Director | Derivative Sale to Issuer | -70,600 | -- |
| 2026-05-26 | Yee Wah Hui | Independent Director | Derivative Sale to Issuer | -19,000 | -- |
| 2026-03-17 | Yat-Gai Au | Chairperson & CEO | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Wing Yan Lo | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Yee Wah Hui | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Yat-Pui Au | Chief Business Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Hoor Han Lo | Independent Director | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:34:41 · For reference only, not investment advice and not tailored to your situation.
Regencell Bioscience discussion 0 comments